Table 1.
The NSCLC Baseline Characteristics of Included Studies.
| Author | Year | Country | Type of study | Type of inhibitor | Sample (Y/N) | Time between ATB exposure and first ICIs | HR for PFS (95%CI) | HR for OS (95%CI) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Beforea | Duringa | Aftera | |||||||||
| 1 | Kaderbhai | 2017 | France | Retrospective | Nivolumab | 74 (15/39) | [−90,0] | During | NA | 0.89 [0.47-1.86] | NA |
| 2 | Thompson | 2017 | United States | Retrospective | Nivolumab | 74 (18/56) | NA | NA | [0,45] | 2.5 [1.56-5.41] | 3.5 [1.49-8.21] |
| 3 | Derosa | 2018 | France | Retrospective | PD-L1/CTLA-4 | 239 (48/191) | [−30,0] | NA | NA | 1.3 [0.9-1.8] | 2.5 [1.6-3.7] |
| 243 (68/175) | [−60,0] | NA | NA | 1.2 [0.9-1.7] | 2.0 [1.3-3.2] | ||||||
| 4 | Huemer | 2018 | Austria | Retrospective | Nivolumab /Pembrolizumab | 30 (11/19) | [−30,0] | NA | [0,30] | 2.5 [1.08-5.78] | 4.29 [1.08-16.98] |
| 5 | Routy | 2018 | France | Retrospective | PD-1/PD-L1 | 140 (−/−) | [−60,0] | NA | [0,30] | 0.89 [0.58-1.34] | 2.31 [1.40-3.83] |
| 6 | Hakozaki | 2019 | Japan | Retrospective | Nivolumab | 90 (13/77) | NA | NA | [0,30] | 2.02 [0.70-5.83] | 2.03 [1.03-3.99] |
| 7 | Kim | 2019 | Korea | Retrospective | PD-1/PD-L1/CTLA-4 | 131 (60/71) | [−60,0] | NA | NA | 2.397 [1.28-4.42] | 3.843 [1.74-8.47] |
| 8 | Pinato | 2019 | United Kingdom | Retrospective | PD-1/PD-L1 | 119 (−/−) | [−30,0] | During | NA | NA | 3.40 [1.90-6.10] |
| 9 | Rounis | 2019 | Greece | Retrospective | ICIs | 44 (−/−) | [−30,0] | During | NA | 2.76 [1.80-6.40] | 4.6 [1.70-12.0] |
| 10 | Schett | 2019 | Switzerland | Retrospective | Nivolumab Pembrolizumab Atezolizumab |
218 (33/185) | [−60,0] | NA | NA | 2.20 [1.50-3.40] | 2.80 [1.70-4.50] |
| NA | During | NA | 0.86 [0.61-1.22] | 1.1 [0.75-1.63] | |||||||
| NA | NA | [0,30] | 1.15 [0.69-1.93] | 0.86 [0.46-1.59] | |||||||
| [−60,0] | During | NA | 1.27 [0.94-1.71] | 1.74 [0.75-3.99] | |||||||
| 11 | Zhao | 2019 | Chinese | Retrospective | PD-1 inhibitor | 109 (20/89) | [−30,0] | NA | [0,30] | 3.13 [1.70-5.56] | 2.86 [1.30-6.25] |
| 12 | Galli | 2019 | Italy | Retrospective | ICIs | 157 (27/30) | NA | During | NA | 1.5 [0.83,2.70] | 2.02 [0.61-6.65] |
| 13 | Ouaknine | 2019 | France | Retrospective | Nivolumab | 72 (30/42) | [−60,0] | NA | [0,30] | 1.6 [0.6-2.2] | 2.2 [1.10-4.80] |
| 14 | Huemer | 2019 | Austria | Retrospective | PD-1/PD-L1 | 142 (62/80) | [−30,0] | NA | [0,30] | 1.02 [0.69-1.50] | 0.91 [0.57-1.45] |
a Time between ATB exposure and first ICIs, before the ICI treatment initiation; after the ICI treatment initiation; during the ICI treatment initiation.